17289-53-1

Basic information

• Product Name: N-(2,4-dimethylphenyl)-N~2~,N~2~-diethylglycinamide
• Synonyms: acetamide, 2-(diethylamino)-N-(2,4-dimethylphenyl)-; N-(2,4-Dimethylphenyl)-N~2~,N~2~-diethylglycinamide
• CAS NO: 17289-53-1
• Molecular Formula: C₁₄H₂₂N₂O
• Molecular Weight: 234.3373
• Mol File: 17289-53-1.mol
• Article Data: 1

Chemical Properties

• Boiling Point: 361.7°C at 760 mmHg
• Flash Point: 172.6°C
• Density: 1.026g/cm³
• Vapor Pressure: 2.03E-05mmHg at 25°C
• Refractive Index: 1.547
• CAS DataBase Reference: N-(2,4-dimethylphenyl)-N~2~,N~2~-diethylglycinamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2,4-dimethylphenyl)-N~2~,N~2~-diethylglycinamide(17289-53-1)
• EPA Substance Registry System: N-(2,4-dimethylphenyl)-N~2~,N~2~-diethylglycinamide(17289-53-1)

Safety Data

• Hazardous Substances Data: 17289-53-1(Hazardous Substances Data)

Usage

General Description

N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide is a chemical compound with the molecular formula C16H25N2O. It is a glycinamide derivative that is often used as an intermediate in the synthesis of pharmaceuticals. This chemical is known for its potential use as an inhibitor in the treatment of cancer and other diseases. It has also been studied for its antibacterial activity against certain strains of bacteria. Additionally, research has shown that N-(2,4-dimethylphenyl)-N2,N2-diethylglycinamide may have potential antiviral properties, making it a compound of interest for further investigation in the field of medicine and drug development.

Upstream product

• 95-68-1 2,4-Xylidine 
• 39106-10-0 2-chloro-N-(2,4-dimethylphenyl)acetamide 
• 109-89-7 diethylamine 

Relevant articles and documents

Synthesis and antispasmodic activity of lidocaine derivatives endowed with reduced local anesthetic action

The present structure-activity relationship (SAR) study focused on chemical modifications of the structure of the local anesthetic lidocaine, and indicated analogues having reduced anesthetic potency, but with superior potency relative to the prototype in preventing anaphylactic or histamine-evoked ileum contraction. From the SAR analysis, 2-(diethylamino)-N-(trifluoromethyl-phenyl) and 2-(diethylamino)-N-(dimethyl-phenyl) acetamides were selected as the most promising compounds. New insights into the applicability of non-anesthetic lidocaine derivatives as templates in drug discovery for allergic syndromes are provided.